On-X trial could expand valve's use
This article was originally published in Clinica
Austin, Texas-based On-X Life Technologies has completed enrolment in the high-risk aortic valve replacement patient group in a trial of its mechanical heart valve. If the trial is successful, the On-X valve may become the only mechanical heart valve that does not require recipients to take large quantities of anticoagulant medication.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.